Thompson Siegel & Walmsley LLC Puma Biotechnology, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $6.71 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding PBYI
# of Institutions
103Shares Held
29MCall Options Held
60.6KPut Options Held
16.3K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.8 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.22 Million0.42% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.88MShares$8.67 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.93 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $137M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...